ストックスクリーナーアプリを入手
0.00
100.00%
-0.7206
Cyclo Therapeutics Inc (CYTH) 最新ニュース
Rafael Holdings Elects N. Scott Fine as Vice Chairman - TipRanks
Rafael Holdings elects Scott Fine as ex-officio director and amends bylaws - Investing.com Nigeria
Rafael Holdings elects Scott Fine as ex-officio director and amends bylaws By Investing.com - Investing.com South Africa
Niemann-Pick Disease Market Forecast 2034: Clinical Trials, - openPR.com
Niemann-Pick Disease Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Treatment, Therapies and Companies by DelveInsight - The Globe and Mail
Niemann-Pick Disease Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Treatment, Therapies And Companies By Delveinsight - Menafn.com
Rafael Holdings, Inc.(NYSE: RFL) dropped from Russell Microcap Growth Index - MarketScreener
RFL SEC FilingsRafael Holdings 10-K, 10-Q, 8-K Forms - Stock Titan
Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data - The Manila Times
Major Breakthrough: Phase 3 Trial for Fatal Rare Disease NPC1 Gets Critical DMC Approval to Continue - Stock Titan
Rafael Holdings Advances Phase 3 Study for NPC1 Treatment - TipRanks
Rafael Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2025 - MarketScreener
Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results - The Manila Times
GSK taps Sanofi vet to lead vaccine R&D; Bristol Myers names head of corporate affairs - Endpoints News
Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering - The Manila Times
Rafael Closes $25 Million Rights Offering - marketscreener.com
Rafael Holdings Announces Final Results And Closing Of Rights Offering - MarketScreener
Rafael CEO Backs $25M Rights Offering to Fund Critical Phase 3 Rare Disease Drug Trial - Stock Titan
Niemann-Pick Disease Market Insights: Key Trends and Developments Across Different Types of Niemann-Pick Disease | DelveInsight - SINA HONG KONG LIMITED
Niemann-Pick Disease Market Insights: Key Trends and - GlobeNewswire
Niemann-Pick Disease Market Forecast 2024-2031: Emerging - openPR.com
Niemann-Pick Disease Type C Treatment Market Forecast 2025-2034:NORTHEASTNORTHEAST - NORTHEAST - NEWS CHANNEL NEBRASKA
Niemann-Pick Disease Type C Market to Expand Significantly - openPR.com
Zevra Cashes in on First FDA-Approved NPC Treatment with PRV - Genetic Engineering and Biotechnology News
RFL stock touches 52-week low at $1.28 amid market challenges - Investing.com
RFL stock touches 52-week low at $1.28 amid market challenges By Investing.com - Investing.com India
Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trap - The Manila Times
Rafael Holdings Rights Offering: $25M Deal Terms Revealed, May 29 Deadline Approaches - Stock Titan
Rafael : to Present at LD Micro Investor Conference - marketscreener.com
SEC Form 424B3 filed by Rafael Holdings Inc. - Quantisnow
Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results - ADVFN
Rafael announces revised subscription rights in connection with offering - TipRanks
Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™ - The Manila Times
Rafael Holdings Launches $25M Rights Offering: Key Dates and Terms Investors Must Know - Stock Titan
Upcoming Stock Splits This Week (May 5 to May 9) – Stay Invested - TipRanks
Hercules Capital: Q1 Earnings Snapshot - marketscreener.com
Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™ - The Manila Times
Rafael Holdings Secures Future: $25M Rights Offering Powers Critical Phase 3 Drug Launch Plans - Stock Titan
Rafael Holdings' $25M Rights Offering: A High-Stakes Bet on Trappsol® Cyclo™ - AInvest
Cyclo Therapeutics (NASDAQ:CYTH) and Genfit (NASDAQ:GNFT) Financial Comparison - Defense World
Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role - The Manila Times
Rafael Holdings Strengthens its Focus on the Development of Trappsol Cyclo and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role - marketscreener.com
Rafael Holdings Announces Leadership Transition Following Merger with Cyclo Therapeutics and Full Enrollment of TransportNPC™ Phase 3 Trial for Niemann-Pick Disease Treatment - Nasdaq
Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces ... - Bluefield Daily Telegraph
Rafael Holdings Pivots to Breakthrough Rare Disease Drug Development as Leadership Changes - Stock Titan
Form 8-KCurrent report - ADVFN
Contrasting BioNTech (NASDAQ:BNTX) and Cyclo Therapeutics (NASDAQ:CYTH) - Defense World
Rafael Holdings finalizes merger with Cyclo Therapeutics By Investing.com - Investing.com South Africa
Rafael Closes Merger With Cyclo Therapeutics - MarketScreener
Rafael Holdings and Cyclo Therapeutics Merge - citybiz
Rafael Holdings Completes Merger With Cyclo Therapeutics Following Shareholder Approvals - MarketScreener
Cyclo Therapeutics Merges with Rafael Holdings - TipRanks
Rafael Holdings Completes Merger with Cyclo Therapeutics - TipRanks
Rafael Holdings finalizes merger with Cyclo Therapeutics - Investing.com
Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals - GlobeNewswire
0.87%
0.80%
大文字化:
|
ボリューム (24 時間):